• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Abstract PURPOSE: The goal of this study was to compare the relative efficacy and safety of different types of interventions for stroke prevention in patients with cardiovascular and cerebrovascular diseases. METHODS: This network meta-analysis (NMA) was conducted with a random effects model of Bayesian framework using Stata version 12.0. Odds ratios (ORs) and their credible intervals (CrIs) were applied for the efficacy and safety evaluation of various medical interventions, including aspirin, dipyridamole, ticlopidine, warfarin, and apixaban. In addition, the ranking of probability of every clinical outcome...
Source: Clinical Therapeutics - June 10, 2017 Category: Drugs & Pharmacology Authors: Sun Q, Chang S, Lu S, Zhang Y, Chang Y Tags: Clin Ther Source Type: research

Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives
Publication date: Available online 3 May 2016 Source:Journal of Pharmacological Sciences Author(s): Toshinori Takagi, Hideaki Hara Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including antiplatelet and vasodilatation effects and protective effects on endothelial cells. Cilostazol also reportedly reduced stroke recurrence, poststroke intracranial hemorrhaging, and extracranial bleeding in a meta-analysis. Although it is known that cilostazol has the potential to suppress hemorrhagic stroke, the precise mechanisms remained unclear. Therefore, we evaluated the protective effects ...
Source: Journal of Pharmacological Sciences - June 15, 2016 Category: Drugs & Pharmacology Source Type: research

Antiplatelet treatment in stroke: new insights.
CONCLUSIONS: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy. PMID: 27291399 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 8, 2016 Category: Drugs & Pharmacology Authors: Milionis H, Liontos A, Vemmos K, Spengos K Tags: Curr Pharm Des Source Type: research

Pages: 1  2